These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36439155)

  • 1. Case report: Local cryoablation combined with pembrolizumab to eliminate lung metastases from ovarian clear cell carcinoma.
    Meng L; Zhang Z; Zhang X; Zhang X; Wei Y; Wu B; Xue X; Zhang X; He X; Xiao Y
    Front Immunol; 2022; 13():1006500. PubMed ID: 36439155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.
    Li X; Xu J; Gu X; Chen L; Wu Q; Li H; Bai H; Yang J; Qian J
    Front Immunol; 2021; 12():740790. PubMed ID: 34733279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
    Descourt R; Chouaid C; Pérol M; Besse B; Greillier L; Bylicki O; Ricordel C; Guisier F; Gervais R; Schott R; Auliac JB; Robinet G; Decroisette C
    Future Oncol; 2021 Aug; 17(23):3007-3016. PubMed ID: 34156285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryoablation and immune synergistic effect for lung cancer: A review.
    Tian Y; Qi X; Jiang X; Shang L; Xu K; Shao H
    Front Immunol; 2022; 13():950921. PubMed ID: 36389781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
    Tang Y; Li Y; Zhang L; Tong G; Ou Z; Wang Z; Zhang H; Qiao G
    Thorac Cancer; 2020 Apr; 11(4):1094-1098. PubMed ID: 32077636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis.
    Xiong L; Cai Y; Zhou X; Dai P; Wei Y; Zhao J; Tang H
    Future Oncol; 2022 Mar; 18(7):883-896. PubMed ID: 34825576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review.
    Katzman D; Wu S; Sterman DH
    J Thorac Oncol; 2018 May; 13(5):624-635. PubMed ID: 29391289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control.
    Gardner CS; Ensor JE; Ahrar K; Huang SY; Sabir SH; Tannir NM; Lewis VO; Tam AL
    J Bone Joint Surg Am; 2017 Nov; 99(22):1916-1926. PubMed ID: 29135665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy.
    Velez A; DeMaio A; Sterman D
    Front Immunol; 2023; 14():1203539. PubMed ID: 37671163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Percutaneous Image-Guided Microwave Ablation and Cryoablation for Sarcoma Lung Metastases: A 10-Year Experience.
    Bourgouin PP; Wrobel MM; Mercaldo ND; Murphy MC; Leppelmann KS; Levesque VM; Muniappan A; Silverman SG; Shepard JO; Shyn PB; Fintelmann FJ
    AJR Am J Roentgenol; 2022 Mar; 218(3):494-504. PubMed ID: 34612679
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
    Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
    Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
    Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
    Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
    How JA; Jazaeri A; Westin SN; Sood AK; Ramondetta LM; Xu M; Abonofal A; Karp DD; Subbiah V; Stephen B; Rodon JA; Yang F; Naing A
    Invest New Drugs; 2021 Jun; 39(3):829-835. PubMed ID: 33415580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
    Xue L; Chen B; Lin J; Peng J
    Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab in the first-line treatment of advanced head and neck cancer.
    de Sousa LG; Ferrarotto R
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1321-1331. PubMed ID: 34689660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.